KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas
  
KalVista gets FDA approval in HAE about three weeks after the PDUFA date (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business